Contact & Referrals
Structured referral and professional enquiry pathways for complex ABI cases.
We accept referrals where:
- ABI diagnosis is confirmed
- Treatment resistance is present
- Governance requirements can be satisfied
Professional Referral
Cann-ABI Clinical Pathway
This form is for Case Managers, Deputies, solicitors and clinical professionals referring individuals with Acquired Brain Injury.
All referrals are reviewed prior to assessment scheduling.
“What Happens Next ?"
Referral reviewed within 3 working days
Eligibility confirmation
Assessment scheduling
Prefer to Discuss Before Referring?
We welcome preliminary discussions for complex cases where suitability is uncertain.
Professional Enquiry
For case managers, deputies, clinicians and legal professionals seeking guidance on suitability, referral criteria or complex cases.
This form is not a referral submission.
“What Happens Next?"
We’ll be back in touch with any required information with 2 working days
We’ll arrange a call to discuss in detail using the availability given earliest convenience
- We’ll discuss the potential necessary next steps
General Enquiries
For general questions from families, patients and non-professional enquiries.
Professional referrals should use the referral pathway.
This service primarily operates via professional referral pathways for complex ABI cases.
General enquiries will be directed to appropriate information where possible.
Frequently Asked Questions
The information provided addresses common enquiries about our clinical pathway, legal framework, safety processes and treatment approach.
If your question is not covered, our team can provide further guidance through the appropriate enquiry pathway.
CBMPs may be considered where conventional treatments have not adequately controlled symptoms such as agitation, anxiety or sleep disturbance, or where side effects have been problematic. While research into the use of Cannabis-Based Medicinal Products (CBMPs) for Acquired Brain Injury (ABI) is still evolving, early clinical evidence and patient reports suggest they may play a supportive role in managing complex, treatment-resistant symptoms.
For many ABI survivors, CBMPs—which contain varying ratios of CBD and THC—are considered for their potential to alleviate neuropathic pain, spasticity, severe sleep disturbances, and secondary anxiety. Emerging studies also highlight the neuroprotective properties of certain cannabinoids, which may assist in modulating neuroinflammation.
Treatment may aim to support:
Emotional regulation
Sleep stabilisation
Anxiety reduction
Behavioural control
Harm reduction where illicit use exists
No. CBMPs do not reverse brain injury. They may support management of symptoms in selected cases.
No. Suitability depends on individual factors including psychiatric history, cardiovascular health and risk profile.
Treatment may not be appropriate where there is:
Active psychosis
Severe cardiovascular instability
High risk of adverse psychological reactions
Inability to meet governance requirements
Adverse effects are possible and may include anxiety, cognitive slowing or cardiovascular changes. This is why structured monitoring is essential.
Where appropriate, structured prescribing may reduce risks associated with unregulated products and exploitation. Each case is assessed individually.
The aim is stabilisation and risk reduction, not reinforcement of dependency.
Treatment may include oils or vaporised products delivered via medical-grade devices. Smoking is not permitted.
Frequency depends on the monitoring tier and clinical stability. Monthly reviews are typical.
Outcomes vary but may include improved sleep, reduced agitation and enhanced stability in daily functioning.
Treatment may be adjusted or discontinued where benefits are insufficient or risks increase.